Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Haematologica - 1 Jun 2017

Gunawan Arief S, McLornan Donal P, Wilkins Bridget, Waghorn Katherine, Hoade Yvette, Cross Nicholas C P, Harrison Claire N

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Cell Count
Share to Bone Marrow
Share to Janus Kinase 1
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to Receptors, Colony-Stimulating Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 28302714
DOI: 10.3324/haematol.2017.163790
PMCID: PMC5451352

Genes

JAK1
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.PMID 28302714Read ↗

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.Semantic proximity Read ↗

Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for CSF3R T618I Mutant Chronic Neutrophilic LeukemiaSemantic proximity Read ↗

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.Semantic proximity Read ↗

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.Semantic proximity Read ↗

Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinibSemantic proximity Read ↗

Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.Semantic proximity Read ↗

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemiaSemantic proximity Read ↗

Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.Semantic proximity Read ↗

Research progress on the mechanisms of CSF3R mutations in leukemogenesis and treatment strategiesSemantic proximity Read ↗

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.Semantic proximity Read ↗

Current strategies in the diagnosis and management of chronic neutrophilic leukemia.Semantic proximity Read ↗

Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.